2021 Frost & Sullivan Annual Conference January 18, 2021 “Lead Innovation and Forge Ahead” Frost & Sullivan Annual Conference Grandly held at the Shanghai Bolei Li Hotel In the toast speeches by Dr. Wang Xin, Global Partner and President of Greater China at Frost & Sullivan, and Mr. Wang Chenhui, Managing Partner and Executive Vice President of Greater China at Frost & Sullivan, all Frost & Sullivan employees raised their glasses to celebrate, officially kicking off the annual conference. As a global growth consulting firm, Frost & Sullivan integrates nearly 60 years of consulting experience globally, has served the booming Chinese market with dedication for 23 years, and helps clients accelerate their business growth with a global perspective, achieving industry benchmarks in growth, innovation, and leadership.   Using rich professional market knowledge and consulting tools, Frost & Sullivan has helped numerous clients achieve strategic goals, including Fortune Global 1000 companies, emerging enterprises, and investment institutions.     Unite as one to create more achievements Frost & Sullivan deeply cultivates the global and Chinese capital markets, providing comprehensive investment and financing services for enterprises. In recent years, Frost & Sullivan China has successfully helped nearly a thousand domestic and foreign companies list and raise funds on major global capital markets, serving over ten thousand listed companies.   In 2020, Frost & Sullivan continued its excellent performance, assisting hundreds of companies including JD Health, China Resources Vanguard, Popomart, Blue Moon, Simore International, Yunding New York, Mingyuan Cloud, Nongfu Spring, Best Buy China, Home Group, New Oriental Education, Midea Youpin, and One Education to successfully list in Hong Kong or overseas, accounting for nearly 60% of the advisory market share for companies going public in Hong Kong. Last year, Frost & Sullivan not only continued to firmly hold the top position in the advisory market for Hong Kong IPOs but also retained its leading position in the advisory market share for overseas IPOs, further expanding its market influence.     Lead Innovation and Transform and Upgrade Frost & Sullivan seizes opportunities of the times, is enterprising, transforms and upgrades, and continuously improves service quality. From selecting high-quality enterprises to providing professional knowledge, from enterprise growth consulting to initial public offerings, from capital matching to market value management, based on serving the Hong Kong and overseas capital and financial markets, Frost & Sullivan further leverages its global experience in the field of innovation to build a distinctive A-share and Science and Technology Innovation Board (STAR Market) service platform, considered the most powerful, professional, and influential industry research institution in the industry.     Rooted in China, deepen layout in Greater China The Greater China region is one of the most important core areas of Frost & Sullivan's global layout. Since opening its first office in Beijing in 1998, it has now established offices in eight locations: Beijing, Shanghai, Shenzhen, Nanjing, Chengdu, Xi'an, Hong Kong, and Taipei. In 2020, the second office in Shanghai welcomed its relocation, marking a new starting point for Frost & Sullivan's transformation and upgrade into an innovative consulting institution and also indicating Frost & Sullivan's firm determination to further deepen its layout in Greater China. The steady and rapid development of Frost & Sullivan is inseparable from the efforts of every employee. To demonstrate the power of role models, at this annual conference, Frost & Sullivan specially set up six awards: the Frost & Sullivan Rising Star Award, the Frost & Sullivan Outstanding Analyst Award, the Frost & Sullivan 5-Year Outstanding Contribution Award, the Frost & Sullivan 10-Year Contribution Award, the Frost & Sullivan Model Worker Award, and the Frost & Sullivan President's Special Award, to commend a group of employees who have performed outstandingly and excellently.   Based on a new starting point, Embark on a new journey. All Frost & Sullivan employees will as always delve deeply into excellence in service, understand industry trends, and help client enterprises grasp the future. In 2021, we also wish Frost & Sullivan continued prosperity and new heights.

On January 20, 2021, the 'Frost & Sullivan' event at the 2021 Yanxi HiMed Medical Innovation Carnival, themed 'Remaining True to Our Original Aspiration', was successfully held in the HiMed International Medical Innovation Space. As a globally renowned growth consulting firm, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') combines nearly 60 years of consulting experience across the world. For 23 years, it has dedicated itself to serving the booming Chinese market and has made the health industry one of its core areas of focus. Over the past sixteen years, Frost & Sullivan's healthcare team has provided financing financial advisory, IPO industry advisory, technical advisory, strategic advisory, management advisory, and other services for hundreds of outstanding domestic and international biopharmaceuticals, medical devices, healthcare services, and internet healthcare enterprises. It is a leader and witness to the development of China's pharmaceutical industry and has been specially invited to attend this summit forum to deliver a keynote speech at the general session.   main question act speak At the event site, Mr. Yang Xiaocheng, Partner of Frost & Sullivan Greater China and Dean of the Frost & Sullivan China Research Institute, delivered a keynote speech titled 'The Chinese Medical Market in the Face of Great Changes'.   Last year, affected by the COVID-19 pandemic, the biotechnology industry has been a focus of market attention. Yang Xiaocheng pointed out that "Innovation begins with technology and is achieved through capital." The biotechnology industry is a typical technology-intensive, innovation-driven sector. The inherent uncertainty of industrial development makes it difficult to combine the biomedical field with traditional financial markets, which are precisely matched by the characteristics of shared interests and risks in the capital market. From a global perspective, driven by both technological progress and demand growth, the biotechnology industry has entered a golden period of development. Since 2014, biopharmaceutical-related companies have accounted for the largest proportion in the U.S. market IPO industry. From 2017 to 2019, the number of NASDAQ pharmaceutical company IPOs reached 50, 86, and 79 respectively, showing a decrease in 2019, but the total fundraising amount still rose to reach 72.34 billion yuan. Overseas investors continue to show enthusiasm for the pharmaceutical industry. The Hong Kong stock market has grown steadily, and its attractiveness is constantly strengthening. From 2017 to 2019, the number of Hong Kong stock market pharmaceutical company IPOs increased from 6 to 17, with the total fundraising amount for the pharmaceutical sector reaching 33.67 billion yuan in 2019.   He believes that with the launch of the Sci-tech Innovation Board and the acceleration of IPO review speed, the role played by the pharmaceuticals and biotechnology sectors in China's capital market will gradually increase. Since most biopharmaceutical companies are characterized by high upfront R&D investment, long investment cycles, high risks but also long-term high returns, their net profits in the early stages are relatively low, or even non-existent. The trial implementation of the registration-based system on the Sci-tech Innovation Board has given these companies greater inclusivity, no longer treating net profit as a rigid standard, but rather taking into account net profit, R&D capabilities, the industry the company is in, and development prospects. 'The fifth set of criteria allows unprofitable enterprises to go public. Pharmaceutical companies only need one core product to have completed phase II clinical trials to apply for listing on the Sci-tech Innovation Board (with an expected market value of not less than 4 billion yuan), bringing huge opportunities for biopharmaceutical companies to go public,' he said.   Yang Xiaocheng is full of anticipation for the development of the biotechnology industry. He said: "We believe that in the future, a group of domestic biotechnology companies with innovative technologies and products will emerge, achieving success through financing in the capital market."   It is reported that as a national-level technology enterprise incubator, Yanyixitang & HiMed platform organizes cross-year forums at the end of each year to promote exchanges and cooperation among incubated enterprises. The forum invites industry experts from various fields such as production, academia, research, investment, incubation, and application to jointly discuss the general trends and investment directions of the medical industry in 2021.

Against the backdrop of digitalization, networking, and intelligence, the International Cybersecurity Industry Event - Beijing Cybersecurity Conference (BCS) has emerged as a necessity. The conference focuses on current and future cybersecurity industry development, international cooperation, capital investment, cutting-edge technologies, new scenario applications, and talent cultivation, and builds a world-class exchange and cooperation platform involving government, industry, enterprises, capital, academia, and application. Over the years, the Beijing Cybersecurity Conference (BCS) has attracted security leaders from institutions, organizations, and enterprises from different countries and regions, attracting widespread attention and becoming an influential industry event in the cybersecurity sector.   The establishment of the BCS Expert Advisory Committee aims to gather industry expert forces and provide in-depth insights, foresight, and high-value perspectives on the cybersecurity industry. The Expert Advisory Committee consists of senior experts from industry associations, research institutions, enterprises, and other sectors. Mr. Wang Chenhui, Managing Partner and General Manager of Frost & Sullivan's Greater China region, was invited to serve as a member of the BCS Expert Advisory Committee.   Frost & Sullivan has been deeply involved in the field of cybersecurity for many years, collaborating closely with leading enterprises in the industry and tracking the latest information and developments in depth. Frost & Sullivan's research shows that in recent years, with the rapid development and popularization of internet and information technology, especially the progress of IoT and 5G network technologies, cybersecurity issues have received increasing attention, and their priority has gradually risen among governments and enterprises. To build a strong "moat" for cybersecurity, governments and enterprises will increase investment in cybersecurity, adopt more targeted security management solutions covering core links, gradually transform cybersecurity from passive defense to active defense, so that cybersecurity systems can not only resist cyberattacks but also prevent them before they occur.   Driven by national policy support, technological development, and vendor demand, Frost & Sullivan expects that in the coming years, the penetration rate of cybersecurity will continue to rise, while at the same time, the cybersecurity industry will remain highly active, continuously emerging with new technological innovation solutions to create a safer and more trustworthy online environment for governments and enterprises.

FT Chinese Network Tourism is one of Hong Kong's four pillar industries and has always been an important force supporting local employment. However, the sudden outbreak of the pandemic last year dealt a severe blow to the local tourism economy, leading to a sharp increase in unemployment rates in related sectors. On January 11th, FT Chinese Network wrote an article discussing the transformation path for Hong Kong's tourism industry to break through after the pandemic, suggesting that Hong Kong can alleviate difficulties by vigorously developing high-end medical tourism. In demonstrating the development space and growth potential of Hong Kong's medical tourism industry, data from Frost & Sullivan were directly cited.   # Frost & Sullivan's insights 01 The total expenditure on private medical care in Hong Kong reached HK$869 billion in 2019 and is expected to grow at a compound annual average rate of 7.6%, reaching HK$1340 billion by 2025; the global medical tourism industry is predicted to reach $658 billion by 2025, with Asia-Pacific accounting for about 40%. If Hong Kong can capture 10% of the Asia-Pacific market share, it will additionally increase revenue by about HK$200 billion, expanding the overall market size to HK$1,540 billion. 02 With such a huge industrial space, Hong Kong urgently needs to seize the current golden opportunity to extend into the high-end medical tourism market.   The global COVID-19 pandemic in 2020 inevitably hit Hong Kong's tourism market hard. From January to October last year, the number of visitors to Hong Kong plummeted by 92.9%. The unemployment rate in the consumer tourism-related industries rose sharply to 11.7% in the third quarter, and this data does not reflect the situation after the grounding and layoffs of Cathay Pacific Dragon Airlines in October that year and the completion of the government's employment support fund. Hong Kong's tourism industry itself relies on a single market, and its 'quantity-high-value' structural problem is difficult to cope with in the post-pandemic tourism ecosystem.   As one of Hong Kong's four pillar industries, in addition to contributing to GDP, tourism and related industries have always been an important force supporting local employment. Hong Kong must focus on developing diversified high-profit tourism products. The medical tourism market not only has high profits but also makes full use of Hong Kong's inherent tourism and medical resources, and Hong Kong has a concentrated industrial chain and a highly mature capital market. Therefore, efforts should be made to develop 'small quantity, high value' products to attract the wealthy class in emerging markets for high-end medical tourism.   In recent years, various regions around the world have been competing for this sunrise industry of healthcare tourism. The World Health Organization predicts that by 2020, healthcare-related services will become the largest and fastest-growing sunrise industry globally, accounting for 22% of global GDP together with leisure tourism. Among them, China is a major country in the overseas healthcare tourism market demand. According to a survey conducted by Shengnuojiayi, an overseas medical service provider in China at the beginning of 2020, 65% of the people who went abroad for medical treatment in 2019 came from high-income entrepreneurs and executives, while the United States, the United Kingdom, and Japan accounted for 99% of the overseas medical treatment market. Undoubtedly, Hong Kong's tourism resources are exceptionally rich, with its medical talents and technology ranking among the world's top. Hong Kong's open market environment can better mobilize international medical resources, and with its close development with the Chinese mainland, it has an absolute advantage in attracting the new rich class from China to travel to Hong Kong for medical tourism under the uncertain prospects of the COVID-19 pandemic in various countries and Sino-US relations.   Why has Hong Kong been overshadowed in the field of medical tourism in recent years?   The author believes that mainly there is no industry cooperation led by policy, social doubts, and the past reliance on China's market dividends by Hong Kong's tourism industry hindered the development of high-end tourism products. In fact, the market has already extended Hong Kong's medical resources to the mainland. For example, the listed Medlink Group in Hong Kong has cooperated with the online medical service brand Penguin Doctor in China, providing more convenient services for residents of the Greater Bay Area to travel to Hong Kong for medical treatment through online platforms and artificial intelligence technology. However, when comparing with other regions in the world's medical tourism markets horizontally, policy support or government-led development models are key to quickly establishing tourism brands in the short term. For example, Thailand implemented the 'Medical Hub of Asia' plan since 2004, and the Japanese government designated medical tourism as a national pillar industry in 2010.   Hong Kong has a highly market-oriented economic structure. As long as there is market demand and policy support, the industry will combine capital to expand its territory. First, market restrictions should be relaxed policy-wise to remove barriers between different industries and markets. For example, accelerating the interoperability of insurance industries between the two places and implementing the 'insurance pass' mechanism expected by the market can greatly enhance medical consumption capabilities. Other policies such as providing tax incentives or subsidies to private institutions that adopt medical technology and provide training, issuing medical tourism visas to passengers with medical needs, relaxing stay times or entry frequencies, etc., are needed. Policy first requires close cooperation among industries to develop attractive medical services and tourism products that can meet the needs of passengers after entering the country. It is best to form an inter-industry medical tourism association to lead cooperation in different fields such as medicine, tourism, aviation, and hotels. To build an international medical tourism city, it also requires government coordination between departments such as the Tourism Development Council and the Department of Health to improve industry supervision and strengthen brand promotion. As long as the vision and thinking are changed, Hong Kong's tourism industry will welcome new impetus for sustainable development.   As for the social doubts about the shortage of land and medical resources in Hong Kong, the author believes that this does not constitute a negative factor for developing the medical tourism market. Hong Kong indeed cannot build large comprehensive medical institutions in its city centers like Japan and Singapore. As long as the government moderately relaxes land use and integrates the private medical market network, it can form point-to-point connection boutique services by taking advantage of the transportation network. The shortage of medical resources in Hong Kong mainly lies in public institutions. The high-end private medical market operates independently and has a certain scale, but it has not formed a medical tourism brand. On the contrary, the author believes that policies should vigorously encourage the development of more medical service training and provide more local employment opportunities. As long as the policies are clear and supervision is in place, developing the high-end private medical market will not compete for public medical resources. On the contrary, if the industry outlook is bright, it can attract more people to engage in the healthcare industry.   According to reports from the Food and Health Bureau of Hong Kong and independent market research firm Frost & Sullivan, the total expenditure on private medical care in Hong Kong reached HK$869 billion in 2019 and is expected to grow at a compound annual average rate of 7.6%, reaching HK$1340 billion by 2025; the global medical tourism industry is predicted to reach $658 billion by 2025, with Asia-Pacific accounting for about 40%. If Hong Kong can capture 10% of the Asia-Pacific market share, it will additionally increase revenue by about HK$200 billion, expanding the overall market size to HK$1,540 billion. With such a huge industrial space, Hong Kong urgently needs to seize the current golden opportunity to extend into the high-end medical tourism market.   *This article is reprinted from 'FT Chinese Network', authored by Chen Huiran, with the original title 'Hong Kong Can Break Through Dilemmas through High-End Medical Tourism'.